...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone.
【24h】

A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone.

机译：帕罗西汀辅助治疗未单独接受认知行为治疗的恐慌症患者的效果的随机，双盲，安慰剂对照研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Both cognitive-behavioral therapy and treatment with selective serotonin reuptake inhibitors (SSRIs) have proved to be effective in the treatment of panic disorder. The present study examined the effects of paroxetine added to continued cognitive-behavioral therapy in patients who were unsuccessfully treated with initial cognitive-behavioral therapy alone. METHOD: 161 patients with panic disorder with or without agoraphobia (DSM-IV criteria) underwent a manual-guided cognitive-behavioral therapy of 15 sessions. Forty-three unsuccessfully treated patients from this group were included in a double-blind, placebo-controlled, next-step treatment study consisting of continued cognitive-behavioral therapy plus adjunctive paroxetine at a dose of 40 mg/day or continued cognitive-behavioral therapy plus placebo. RESULTS: Overall, patients in the cognitive-behavioral therapy plus paroxetine condition improved significantly on agoraphobic behavior (p < .05) and anxiety discomfort (p < .01), whereas patients in the cognitive-behavioral therapy plus placebo condition did not. Effect sizes in the cognitive-behavioral therapy plus paroxetine condition ranged from 1.0 to 1.8 and in the cognitive-behavioral therapy plus placebo condition, from 0.4 to 1.0. CONCLUSION: Patients with panic disorder who are unsuccessfully treated with initial cognitive-behavioral therapy may benefit from the addition of an SSRI as a second treatment modality. The importance of timely evaluation of treatment results is emphasized.
机译：背景：认知行为疗法和选择性5-羟色胺再摄取抑制剂（SSRI）的治疗均已证明可有效治疗恐慌症。本研究检查了帕罗西汀在继续接受认知行为治疗中的效果，这些患者仅接受初始认知行为治疗均未成功治疗。方法：161名患有或没有恐慌症的恐慌症患者（DSM-IV标准）接受了为期15次的手动指导的认知行为治疗。该组中43例未成功治疗的患者被纳入一项双盲，安慰剂对照的下一步治疗研究，该研究包括以40毫克/天的剂量持续进行认知行为疗法和辅助性帕罗西汀或持续进行认知行为疗法加安慰剂。结果：总体而言，认知行为疗法加帕罗西汀治疗的患者在过恐惧心理行为（p <.05）和焦虑不适（p <.01）上有显着改善，而认知行为疗法加安慰剂的患者则没有。认知行为疗法加帕罗西汀的影响范围为1.0到1.8，认知行为疗法加安慰剂的影响范围为0.4到1.0。结论：未通过最初的认知行为治疗成功治疗的恐慌症患者可受益于SSRI作为第二种治疗方式。强调及时评估治疗结果的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号